Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Tildrakizumab

    Tag: tildrakizumab

    You Searched For "Tildrakizumab"
    Sun Pharma ILUMYA phase 3 trial shows significant skin clearance in people with Plaque Psoriasis

    Sun Pharma ILUMYA phase 3 trial shows significant skin clearance in people with Plaque Psoriasis

    Farhat Nasim11 Oct 2019 9:30 AM IST
    New Delhi: Sun Pharmaceutical Industries Ltd. recently announced that one of its wholly-owned subsidiaries presented long-term follow-up data from...
    Sun Pharma records Total Revenue of Rs 8374.36 crore for June quarter

    Sun Pharma records Total Revenue of Rs 8374.36 crore for June quarter

    Medical Dialogues Bureau16 Aug 2019 9:30 AM IST
    Mumbai: India's largest drugmaker Sun Pharmaceutical Industries Ltd. (Sun Pharma) recently reported a consolidated net profit of Rs 1,387.48 crore...
    Sun Pharma enters licensing agreement with CMS for arthritis drug Tildrakizumab

    Sun Pharma enters licensing agreement with CMS for arthritis drug Tildrakizumab

    Medical Dialogues Bureau28 Jun 2019 12:30 PM IST
    The initial tenure of the agreement between Sun Pharma and CMS shall be 15 years from the first commercial sale of Tildrakizumab in Greater China and...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok